肝细胞癌 (HCC) 是非洲第四大常见癌症，与撒哈拉以南非洲地区一样，其总生存期仅为 3 个月。这是受到国内生产总值和人类发展指数较低、缺乏一致的指导方针等因素的影响。2021 年 10 月，为来自非洲和世界其他地区有 HCC 经验的医护人员举办了一次公开论坛。参与者完成了该调查旨在帮助评估北非和南非 (NS)、东非和西非 (EW)、中非 (C) 以及世界其他地区在现实生活中获得筛查、诊断和治疗的情况。 共有 461 名参与者从所有相关专业来看，372 名来自非洲。大多数非洲参与者提供了乙型肝炎疫苗接种以及乙型肝炎和丙型肝炎治疗。超过一半的参与者使用血清甲胎蛋白和超声进行监测。只有 20% 报告使用图像引导诊断性肝活检。巴塞罗那诊所肝癌是最常用的分期系统 (52%)。只有 28% 的 NS 患者和 3% 的 EW 患者可以进行肝脏移植。 C 报告切除的可用性明显较低。局部治疗的可用性范围从 NS 的 94% 到 C 的 62%。索拉非尼是最常用的全身治疗 (66%)。只有 12.9% 的人报告使用其他药物，包括免疫检查点抑制剂。除了 42% 的 NS 患者可以获得瑞戈非尼外，没有提供二线治疗。报告了非洲 HCC 患者护理的相似点和差异。这再次证实了在访问和可用性方面的主要差距，尤其是在 C 领域，而在 EW 领域则稍小一些。呼吁多学科共同努力，以实现并持续降低非洲 HCC 的发病率和死亡率。

Hepatocellular carcinoma (HCC), the fourth most common cancer in Africa, has a dismal overall survival of only 3 months like in sub-Saharan Africa. This is affected by the low gross domestic product and human development index, absence of coherent guidelines, and other factors.An open forum for HCC-experienced health care workers from Africa and the rest of the world was held in October 2021. Participants completed a survey to help assess the real-life access to screening, diagnoses, and treatment in the North and Southern Africa (NS), East and West Africa (EW), Central Africa (C), and the rest of the world.Of 461 participants from all relevant subspecialties, 372 were from Africa. Most African participants provided hepatitis B vaccination and treatment for hepatitis B and C. More than half of the participants use serum alpha-fetoprotein and ultrasound for surveillance. Only 20% reported using image-guided diagnostic liver biopsy. The Barcelona Clinic Liver Cancer is the most used staging system (52%). Liver transplant is available for only 28% of NS and 3% EW. C reported a significantly lower availability of resection. Availability of local therapy ranged from 94% in NS to 62% in C. Sorafenib is the most commonly used systemic therapy (66%). Only 12.9% reported access to other medications including immune checkpoint inhibitors. Besides 42% access to regorafenib in NS, second-line treatments were not provided.Similarities and differences in the care for patients with HCC in Africa are reported. This reconfirms the major gaps in access and availability especially in C and marginally less so in EW. This is a call for concerted multidisciplinary efforts to achieve and sustain a reduction in incidence and mortality from HCC in Africa.